“…Previous studies of the role of estrogen supplementation for women with CF have focused on outcomes of inflammation [9] , [17] , [18] , [19] , pulmonary function [18] , [19] , nutrition [19] , and bone mineral density [20] , [21] . Oral contraceptive use by women with CF has been associated with decreased frequency of acute pulmonary exacerbations, decreased bone mineral density, similar declines in FEV1 and similar BMI compared to women with CF not using oral contraception [17] , [18] , [19] , [20] , [21] .…”